Stableford Capital II LLC Purchases 8,015 Shares of CVS Health Corporation $CVS

Stableford Capital II LLC acquired a new stake in CVS Health Corporation (NYSE:CVS) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 8,015 shares of the pharmacy operator’s stock, valued at approximately $687,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Mn Services Vermogensbeheer B.V. boosted its stake in shares of CVS Health by 1.3% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 375,568 shares of the pharmacy operator’s stock valued at $32,182,000 after purchasing an additional 4,900 shares during the period. Farther Finance Advisors LLC lifted its holdings in CVS Health by 30.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 54,244 shares of the pharmacy operator’s stock worth $4,648,000 after buying an additional 12,718 shares in the last quarter. CoreCap Advisors LLC lifted its holdings in CVS Health by 50.6% in the 3rd quarter. CoreCap Advisors LLC now owns 5,242 shares of the pharmacy operator’s stock worth $449,000 after buying an additional 1,761 shares in the last quarter. Artemis Investment Management LLP boosted its position in CVS Health by 65.6% in the 3rd quarter. Artemis Investment Management LLP now owns 50,481 shares of the pharmacy operator’s stock valued at $4,326,000 after buying an additional 20,000 shares during the last quarter. Finally, Hamlin Capital Management LLC grew its stake in shares of CVS Health by 13.6% during the third quarter. Hamlin Capital Management LLC now owns 1,951,402 shares of the pharmacy operator’s stock valued at $167,216,000 after acquiring an additional 233,794 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Trading Down 0.0%

Shares of NYSE CVS opened at $87.91 on Friday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. The stock’s 50 day moving average price is $93.10 and its two-hundred day moving average price is $92.41. CVS Health Corporation has a 52-week low of $69.51 and a 52-week high of $110.68. The stock has a market capitalization of $112.43 billion, a P/E ratio of 23.26, a PEG ratio of 0.82 and a beta of 0.60.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.71. The business had revenue of $106.10 billion during the quarter, compared to the consensus estimate of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The business’s quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, analysts anticipate that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd will be issued a dividend of $0.6650 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Thursday, October 22nd. CVS Health’s dividend payout ratio is 70.37%.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Aetna’s Medicare Advantage quality ratings are a key positive. More than 69% of Aetna’s Medicare Advantage members are enrolled in plans rated four stars or higher for 2027. Strong CMS Star Ratings could support member retention, enrollment and Medicare Advantage economics, making this the most significant near-term catalyst. Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience
• Positive Sentiment: Investors are positioning for further gains. Traders purchased about 23,271 CVS call options, roughly 33% above typical call volume. This signals increased bullish speculation, although options activity is not a guarantee of sustained share-price appreciation. Traders Buy Large Volume of Call Options on CVS Health
• Positive Sentiment: Long-term pharmacy operations gained greater supply-chain visibility. CVS extended pharmaceutical distribution agreements with Cardinal Health and McKesson through 2032, supporting continuity for its nationwide retail pharmacy network. The company is also expanding access through a pharmacy-focused Boston location.
• Neutral Sentiment: Analysts see potential recovery, but the valuation case remains execution-dependent. Commentary points to recovering Aetna margins, improving pharmacy trends and momentum in CVS Health Services. CVS trades at a discount to industry peers, but investors are watching whether its integrated-care strategy can translate into durable earnings growth.
• Negative Sentiment: 340B pricing pressure remains a headwind. Persistent challenges from the federal 340B drug-pricing program could weigh on pharmacy profitability and offset some of the gains from improved insurance and health-services performance.

Analysts Set New Price Targets

Several research analysts recently commented on CVS shares. Weiss Ratings upgraded CVS Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. HSBC restated a “hold” rating and set a $103.00 price objective on shares of CVS Health in a report on Monday, July 6th. Piper Sandler set a $112.00 target price on CVS Health in a research report on Wednesday, September 9th. Barclays raised their price target on shares of CVS Health from $106.00 to $108.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. lifted their price target on shares of CVS Health from $111.00 to $118.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Twenty-two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $107.24.

About CVS Health

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company’s major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.